Enliven Therapeutics, Inc. $ELVN Position Cut by Commodore Capital LP

by · The Markets Daily

Commodore Capital LP decreased its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 30.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 3,275,000 shares of the company’s stock after selling 1,417,809 shares during the quarter. Enliven Therapeutics comprises 7.4% of Commodore Capital LP’s holdings, making the stock its 3rd biggest position. Commodore Capital LP owned approximately 0.05% of Enliven Therapeutics worth $128,380,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in Enliven Therapeutics in the first quarter valued at approximately $38,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after acquiring an additional 594 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares during the last quarter. Quantbot Technologies LP increased its holdings in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Enliven Therapeutics by 194.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after acquiring an additional 3,490 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $52.95 on Monday. The firm has a market cap of $3.22 billion, a price-to-earnings ratio of -31.71 and a beta of 0.24. The firm’s fifty day moving average price is $45.49 and its 200 day moving average price is $37.43. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $54.88.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Guggenheim initiated coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price objective on the stock. The Goldman Sachs Group lifted their price objective on shares of Enliven Therapeutics from $59.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. HC Wainwright increased their target price on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Finally, Mizuho boosted their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.50.

Check Out Our Latest Research Report on Enliven Therapeutics

Insider Activity

In other news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at $2,233,800. The trade was a 10.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the transaction, the director directly owned 41,884 shares of the company’s stock, valued at $2,114,723.16. This represents a 19.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 26,018 shares of company stock worth $1,113,888. Insiders own 3.00% of the company’s stock.

About Enliven Therapeutics

(Free Report)

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

Recommended Stories

Want to see what other hedge funds are holding ELVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report).